Truist Financial Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $25.00

Keros Therapeutics (NASDAQ:KROS - Get Free Report) had its price objective cut by research analysts at Truist Financial from $43.00 to $25.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Truist Financial's price objective would suggest a potential upside of 99.20% from the company's current price.

A number of other equities research analysts also recently commented on the company. Wells Fargo & Company decreased their target price on Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, February 27th. TD Cowen cut Keros Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. BTIG Research lowered shares of Keros Therapeutics from a "buy" rating to a "neutral" rating in a report on Thursday, December 12th. William Blair downgraded shares of Keros Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Thursday, December 12th. Finally, Oppenheimer lowered their price objective on shares of Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating for the company in a research report on Thursday, January 16th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Keros Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $40.33.

Remove Ads

Keros Therapeutics Stock Up 3.0 %

KROS stock traded up $0.37 during midday trading on Wednesday, hitting $12.55. The company's stock had a trading volume of 903,640 shares, compared to its average volume of 767,467. Keros Therapeutics has a 12 month low of $9.12 and a 12 month high of $72.37. The company has a 50 day moving average of $10.91 and a two-hundred day moving average of $30.62. The firm has a market capitalization of $509.05 million, a price-to-earnings ratio of -2.41 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, topping analysts' consensus estimates of ($1.36) by $0.22. The firm had revenue of $3.04 million during the quarter, compared to analyst estimates of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. On average, analysts anticipate that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the company's stock in a transaction that occurred on Wednesday, April 9th. The stock was bought at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the purchase, the insider now owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. The trade was a 27.01 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 22.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Keros Therapeutics

A number of institutional investors have recently bought and sold shares of the company. AlphaQuest LLC grew its holdings in shares of Keros Therapeutics by 469.0% during the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock worth $57,000 after purchasing an additional 2,964 shares during the period. Virtus ETF Advisers LLC boosted its stake in Keros Therapeutics by 107.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock worth $61,000 after buying an additional 1,998 shares during the period. KLP Kapitalforvaltning AS purchased a new position in Keros Therapeutics during the fourth quarter worth about $90,000. Exchange Traded Concepts LLC acquired a new stake in shares of Keros Therapeutics during the fourth quarter valued at about $99,000. Finally, CANADA LIFE ASSURANCE Co raised its stake in shares of Keros Therapeutics by 207.8% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company's stock valued at $116,000 after acquiring an additional 4,976 shares during the period. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.